1. You are what you exhale Every time that we exhale We release volatile compounds

2. Scientists can analyse our breath They collect all the volatiles …and tell you how healthy are your lungs!

3. Now imagine what we can do… lung information piece of exhaled air

4. The answer is… We are a company that develops medical devices to analyze breath and diagnose “Tuberculosis” and “Aspergillosis” at same TIME! CEO Financials Marketing Operations R&D

5. Why Tuberculosis and Aspergillosis? 7,982 cases of Tuberculosis were notified in the UK in 2013 Aspergillosis affects over 1,000,000 people Over 25,000 deaths are estimated every year 95 % of Tuberculosis occurred in developing countries Over 3,000,000 cases of Aspergillosis were reported worldwide. 12 % of those cases were related to tuberculosis. Over 3,000,000 cases of Aspergillosis were reported worldwide. 12 % of those cases were related to tuberculosis.

6. Why Tuberculosis and Aspergillosis? Tuberculosis and Aspergillosis share the same clinical presentation. The bronchoalveolar lavage to diagnose aspergillosis is invasive and painful.

7. Competitive advantage Detection in 1 min Non-invasive 96.7 % sensitivity 98.3 % specificity Portable Price £40 Price range £75-£1,500 least 12 hours Invasive 64.5% sensitivity 93.2% specificity Immobile Sputum

8. Market Segmentation Market stage: increasing 1.6 billion by 2017 and revenue growth rate is 5.7%. Competitive factors: life span, reliability, availability, product cost, and service quality. Competitive factors -Life span -Reliability -Availability -Product cost -Service quality. USA 42% Asia 21% Germany 11% UK 9% Latin America 16% South Africa 1% Distribution of global market Roche 40% Beckman 10% Siemens 10% Abbott 10% Market share by companies 1.6 billion USD (2017) Market stage Growth rate 5.7%

9. Marketing & advertising strategy Medical advocates Special promotions Advertising & Publicity Hospitals, Point Care Centres, Respiratory Clinics, Nursing Homes Governments, Airports, Immigration, Infection Control & Surveillance Medical Blogs Science daily News and Media BBC report 20 Sept 2015 Conference Email Research white paper Publish Social networks (twiister,Facebook, Insistigarm,you tube) Webinars Document shareing Word of mouth Type intraffic Podcasing Search Engine Optimization

10. Gold & carbon nanoparticles specific to volatile chemicals from Aspergillus and Tuberculosis Breath analysis with gold & carbon nanoparticles Voltron 1.0 Gold and carbon nanoparticles Inferred statistical model of the response Gas chromatography Mass spectrometry Chromatogram result

11. Distribution Channels & Advertising Medical advocates End user Direct Sales 26.7% Distributors 63.5% Online sales 9.8% Special promotions Advertising & Publicity Hospitals, Point Care Centres, Respiratory Clinics, Nursing Homes Governments, Airports, Immigration, Infection Control & Surveillance

12. Company Story Licensing to Omega Diagnostic Ltd (Manufacture) Licensing to Avenzys Medical (Distributor)

13. Operations Year 1 Voltron 2 (Diabetes) Voltron 3 (Cancer) Voltron 4 (Arthritis) R&D Sale of Voltron 1.0 licenses Omega Diagnostic Ltd Designed in the UK Avenzys Medical Conferences Face to face marketing

14. Operations Year 3 Sale of Voltron 1,2,3 licenses Omega Diagnostic Ltd Designed in the UK Avenzys Medical Conferences Face to face marketing Direct sales 40% 60% Surveillance And tech support

15. Operations Year 6 Sale of Voltron 1,2,3,4 licenses Designed in the UK Conferences Face to face marketing 40% 60% Surveillance And tech support Direct sales Volatron1 by Volatronics

16. Financials & Profitability Sales forecast This and the other financials statements are based on best guesses. Relevant info: market analysis indicates that 62% of profit for the biosensor market is generated by distributors, 12% by manufacturers. We license the technology to manufacture and distribute, but we are concerned to develop new products to diagnose lung cancer, diabetes and arthritis. UK is a leading country in research for developing new medical devices, grants of research councils and also the market of infectious diseases is 80% based on LATAM, therefore cheap devices and easy to use are relevant.

17. Financials & Profitability Profit and loss account Cash flow forecast Everything is based on best guesses.

18. Roadmap

19. So what we need?

20. So what’s in it for you?

21. Take home message

22. Q&A slides

23. Advertising plan

24. Risk management

25. Strengths, Weakness, Opportunity & Threats Strengths: Key player in rapid detection kits market Unique and novel detection technique Backed by scientific authorities of the field Focus on product R&D in broadening horizontal applications Challenges Branding International markets Risks management Opportunities Solutions for different invasive diseases. Upgrading the current immobile analysis stations in hospitals and clinics to portable devices Become a self-distributor Large investment in R&D and patenting Customer’s health leads to growth in reputation and increase of clients Threats Competitive threat from companies with emerging technology

26. Human resources Aaron Hernandez Cid (CEO): Aaron is a true entrepreneur, and a co-founder of several start-ups (e.g. Cloudpaper), Starting in "Los Zetas Corp." Juarez, Mexico where he had the role of CEO and continuing to head Beltrán-Leyva Ltd. dealing mostly with oil. Aaron found out from the news about the severe breathing problems his corporation had caused, in fact after suffering from a personal family loss he've decided to start up a company which will provide cheap solutions for any breath detectable illnesses, he teamed up with Evaldez a young researcher and decided to start with fungus detection in lungs. Evaldez Klumbys (R & D): Young researcher, after finishing his PhD in Fungus research and lung deseases etc. he started to look for practical opportunities to make some money. He gained some work experience in the GSK where he has developed a special mask design for breath analysis. He travelled to several conferences where he met Aaaron during one of the Pitch for investment sessions. Evaldez was glad to take the role of R&D director in Volatronics. Aiah Khateb. (Marketing): M.Sc in Microbiology and Infectious Diseases at Calgary's Center of Antimicrobial Resistance, Canada. Winner of Canadian Microbiology Marketing Award, 2014, Victoria AMMI Canada. Has 2 years marketing experience from the Canadian innovation centre. Currently works on identifying novel Molecular Detection & Mechanisms of Antifungal Resistance in Aspergillus fumigatus as a researcher, at University of Manchester. Always felt like there is not enough exposure to the dangers and severity of illnesses related to fungus. As a leading researcher in this field Aiah felt obligated to join any company that will address fungus related illnesses and especially she was happy to take the marketing role as she is very passionate and motivated to rise awareness in this field.

27. Human resources Tania Sanchez Monroy. (Financials): Spending several years in TWAS (The Third World Academy of Sciences) grants committee as a judge and for another 2 years as an advisor in a Governmental “Business and Science” committee of Mexico. Tania has all the skills and networking needed to get the funds and investments and to keep the company profitable Specialities: Strategic Planning, Technology & Innovation Management, Materials science and biomechanics,, Team working, Health industry partnership projects. Leonid Nichman. (HR & Operations): M.Sc Chemistry and Materials science, had 5 years of experience of operations and logistics in a printing corporation. dealing with suppliers, processing orders and building the whole logistics chain. Leonid won the VentureOut prize of 2015 for his ideas for improvements of Graphene production lines. Leonid is a team player and an HR specialist with a long experience of managing and coordinating international and multidisciplinary teams at CERN. Leonid is a polyglot with a deep knowledge of Mandarin which facilitates the collaboration with our manufacturers in China.

28. Mr. Aaron Hernandez Cid CEO Citylabs Nelson St, Manchester M13 9NQ Phone :0161 393 2288 Fax (203) 555-0101 A.Cid@volatronics.com Dr. Evaldez Klumbys Research & Development Citylabs Nelson St, Manchester M13 9NQ Phone :0161 393 2288 Fax (203) 555-0101 E. Klumbys@volatronics.com Ms.Aiah Khateb Marketing & Advertising Citylabs Nelson St, Manchester M13 9NQ Phone :0161 393 2288 Fax (203) 555-0101 A.khateb@volatronics.com Mr.Leonid Nichman HR & Operations Citylabs Nelson St, Manchester M13 9NQ Phone :0161 393 2288 Fax (203) 555-0101 L. Nichman@volatronics.com Ms.Tania Sanchez Monroy Financials Citylabs Nelson St, Manchester M13 9NQ Phone :0161 393 2288 Fax (203) 555-0101 T. Monroy@volatronics.com Mr. Aaron Hernandez Cid CEO Citylabs Nelson St, Manchester M13 9NQ Phone :0161 393 2288 Fax (203) 555-0101 A.Cid@volatronics.com Dr. Evaldez Klumbys Research & Development Citylabs Nelson St, Manchester M13 9NQ Phone :0161 393 2288 Fax (203) 555-0101 E. Klumbys@volatronics.com Ms.Aiah Khateb Marketing & Advertising Citylabs Nelson St, Manchester M13 9NQ Phone :0161 393 2288 Fax (203) 555-0101 A.khateb@volatronics.com Mr.Leonid Nichman HR & Operations Citylabs Nelson St, Manchester M13 9NQ Phone :0161 393 2288 Fax (203) 555-0101 L. Nichman@volatronics.com Ms.Tania Sanchez Monroy Financials Citylabs Nelson St, Manchester M13 9NQ Phone :0161 393 2288 Fax (203) 555-0101 T. Monroy@volatronics.com